Premium
Cytomegalovirus in Solid Organ Transplant Recipients
Author(s) -
Humar A.,
Snydman D.
Publication year - 2009
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2009.02897.x
Subject(s) - medicine , immunology , retinitis , bronchiolitis obliterans , cytomegalovirus , pneumonitis , valganciclovir , disease , nephropathy , transplantation , population , ganciclovir , herpesviridae , human cytomegalovirus , viral disease , lung transplantation , lung , virus , diabetes mellitus , environmental health , endocrinology
CMV infection is a major cause of morbidity in patients receiving solid organ transplants. CMV is widely distributed in the general population with seroprevalence ranging from 30 to 97% (1–3). After primary infection, CMV establishes life-long latency. Without some form of prevention, CMV infection primarily occurs in the first 3 months following transplant. Onset may be delayed in patients receiving CMV prophylaxis.